- UAA Congress 2025

Final Presentation Format

Non-Moderated Poster Abstract

Eposter Presentation

Eposter in PDF Format

Accept format: PDF. The file size should not be more than 5MB

Eposter in Image Format

Accept format: PNG/JPG/WEBP. The file size should not be more than 2MB

Presentation Date / Time

Submission Status

Submitted

Abstract

Abstract Title

Frequency and clinical significance of CDK12 mutation in Metastatic Hormone-sensitive Prostate Cancer

Presentation Type

Non-Moderated Poster Abstract

Manuscript Type

Meta Analysis / Systematic Review

Abstract Category *

Oncology: Prostate

Author's Information

Number of Authors (including submitting/presenting author) *

4

No more than 10 authors can be listed (as per the Good Publication Practice (GPP) Guidelines).
Please ensure the authors are listed in the right order.

Country

China

Co-author 1

SHUN ZHANG explorershun@126.com Nanjing Drum Tower Hospital Department of Urology NAN JING China *

Co-author 2

JUNLONG ZHUANG zhuangjl-2008@163.com Nanjing Drum Tower Hospital Department of Urology NAN JING China -

Co-author 3

xuefeng_qiu@nju.edu.cn Nanjing Drum Tower Hospital Department of Urology NAN JING China -

Co-author 4

HONGQIAN GUO dr.ghq@163.com Nanjing Drum Tower Hospital Department of Urology NAN JING China -

Co-author 5

-

Co-author 6

-

Co-author 7

-

Co-author 8

-

Co-author 9

-

Co-author 10

-

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Co-author 16

Co-author 17

Co-author 18

Co-author 19

Co-author 20

Abstract Content

Introduction

To investigate the frequency and prognostic significance of CDK12 mutation in Metastatic Hormone-sensitive Prostate(mHSPC).

Materials and Methods

The frequency of CDK12 mutation of 91 patients with mHSPC were detected by Next Generation Sequencing(NGS). The clinical information of patients was collected. The prognostic significance of CDK12 mutation was analyzed by time to castration resistance.

Results

We detected CDK12 mutation in 11 of 91(12.09%)patients. There was a significant difference between CDK12 mutation and time to castration resistance(χ2=6.278，P=0.012). Logistic regression analysis showed that CDK12 mutation significantly increased the risk of mHSPC patients progressing to mCRPC stage within 12 months(OR=5.86, 95% CI：1.46-23.49, P=0.013). Also, the ISUP subgroup was an independent risk factor(OR=2.92, 95% CI：1.23-6.92, P=0.015).

Conclusions

The frequency of CDK12 mutation in Chinese population is much higher than that in Caucasian. CDK12 is an important indicator of poor prognostic, which can be used as an effective biomarker to predict the prognosis of patients with mHSPC.

Keywords

Prostate cancer; Metastatic Hormone-sensitive Prostate Cancer; CDK12; Prognostic

Figure 1

https://storage.unitedwebnetwork.com/files/1237/55201fb63c2dea0df150126204760318.png

Figure 1 Caption

Mutation Profiles of 91 Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Figure 2

https://storage.unitedwebnetwork.com/files/1237/bf8e969453b98707d15a263c06475071.png

Figure 2 Caption

Clinical Characteristics of 91 mHSPC Patients

Figure 3

https://storage.unitedwebnetwork.com/files/1237/e069af7a9021451330a569c0b4070519.png

Figure 3 Caption

Logistic Regression Analysis of Factors Associated with Progression to mCRPC

Figure 4

Figure 4 Caption

Figure 5

Figure 5 Caption

Character Count

2059

Vimeo Link

Presentation Details

Session

Date

Time

Presentation Order